SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Tecentriq

EXEL·EXELIXIS, INC.
MIXED
Drug Impact Rating7/10
Trial phase
Phase 3 (NDA under FDA review)
Time to market
The FDA PDUFA target action date for the zanzalintinib + atezolizumab combination is March 3, 2027. If approved, a commercial launch would follow shortly after.
Why 7/10
The next hard catalyst is the FDA PDUFA decision on March 3, 2027 (~4 months away) for the zanzalintinib + atezolizumab (Tecentriq) NDA in previously treated metastatic CRC, a binary event on a major pipeline asset at a company that also has the established Cabometyx franchise, warranting a 7.
Actionable Insight MIXED

The next hard catalyst is the FDA PDUFA decision on the zanzalintinib + atezolizumab (Tecentriq) combination for previously treated metastatic CRC, now set for March 3, 2027 after a 3-month extension. An approval would give Exelixis a second commercial franchise beyond Cabometyx; a CRL or further delay would pressure the stock given the mixed STELLAR-303 data (ITT OS hit, NLM subgroup miss) and the safety signal of 5 treatment-related deaths in the combo arm.

Price Chart

Loading chart...

Executive Summary

Tecentriq (atezolizumab) is Roche/Genentech's PD-L1 checkpoint inhibitor, already approved for multiple cancers including NSCLC, bladder cancer, and most recently (October 2026) adjuvant dMMR colon cancer. For Exelixis (EXEL), Tecentriq is relevant as the immunotherapy partner in their zanzalintinib combination for metastatic colorectal cancer. The STELLAR-303 Phase 3 trial met its primary OS endpoint in the ITT population (HR 0.80, p=0.0045) but missed the second dual primary endpoint in the non-liver metastases subgroup (p=0.1185). The FDA accepted the NDA but extended the review by 3 months to March 3, 2027 after Exelixis submitted updated safety data, including 5 treatment-related deaths in the combo arm. This PDUFA decision is the key near-term catalyst for EXEL.

How It Works

Tecentriq is an immunotherapy (a monoclonal antibody) that blocks a protein called PD-L1 found on cancer cells and immune cells. PD-L1 acts as a 'brake' on the immune system's T-cells, preventing them from attacking tumors. By blocking PD-L1, Tecentriq releases this brake, allowing the immune system to recognize and kill cancer cells. Exelixis is combining Tecentriq with its own drug zanzalintinib, an oral kinase inhibitor that targets multiple cancer-promoting pathways (MET, AXL, VEGFRs) and may enhance the immune response.

Trial Status

The pivotal Phase 3 STELLAR-303 trial (NCT05425940) randomized 901 patients with previously treated non-MSI-H metastatic CRC to zanzalintinib + atezolizumab versus regorafenib. The ITT population met the OS primary endpoint (median OS 10.9 vs 9.4 months; HR 0.80; p=0.0045). The second dual primary endpoint (OS in patients without liver metastases) was not statistically significant (HR 0.83; p=0.1185). Detailed results were published in The Lancet and presented at ESMO 2025. The NDA was accepted with a PDUFA originally set for December 3, 2026, but extended to March 3, 2027 after a major amendment submission.

The Two-Sided Case

▲ Bull Case5
STELLAR-303 is the first Phase 3 trial to show a statistically significant overall survival improvement with an immunotherapy-based regimen in non-MSI-H / MSS metastatic colorectal cancer, a historically immunotherapy-resistant population.
The ITT population met its OS primary endpoint with a hazard ratio of 0.80 (p=0.0045), and median OS was 10.9 months vs 9.4 months for regorafenib.
If approved, the zanzalintinib + atezolizumab combination would be a chemotherapy-free oral + immunotherapy option for heavily pretreated CRC patients with no good alternatives.
Exelixis generated ~$659M in Q3 2026 revenue from its Cabometyx franchise, providing a strong financial base to fund the zanzalintinib launch without dilution.
Institutional accumulation was strong in Q2 2026, with D.E. Shaw, Goldman Sachs, JPMorgan, and Bank of America all adding to positions.
▼ Bear Case5
STELLAR-303 missed its second dual primary endpoint: OS in patients without liver metastases was not statistically significant (HR 0.83, p=0.1185), raising questions about the breadth of the benefit.
The FDA extended the PDUFA by 3 months to March 3, 2027 after Exelixis submitted updated safety and efficacy data classified as a major amendment, signaling potential review concerns.
There were 5 treatment-related deaths in the zanzalintinib + atezolizumab arm versus 1 in the regorafenib arm in STELLAR-303, a safety imbalance the FDA may scrutinize.
The analyst consensus mean price target of ~$55.53 sits well below the current ~$66 stock price, implying the Street sees limited upside from here.
Exelixis faces eventual generic competition to its flagship Cabometyx franchise, which accounts for the vast majority of revenue.

Upcoming Catalysts

  • FDA PDUFA decision for zanzalintinib + atezolizumab in previously treated metastatic CRC: March 3, 2027
  • Topline results from STELLAR-304 (zanzalintinib + nivolumab in non-clear cell RCC): expected H2 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

EXELIXIS, INC. 8-K EXEL ·Originating report

Sources · 9

Hover a chip for the title
1 ir.exelixis.com2 ir.exelixis.com3 targetedonc.com4 fda.gov5 roche.com6 fiercebiotech.com7 gene.com8 talk.bio9 simianx.ai